News & Topics Past News
2018.02.09
Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
2018.02.07
Analyst Report[Update report]: Shared Research updates the report
2018.02.07
SymBio's Mid-Range Plan: FY2018 to FY2021
2018.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
2018.02.07
Notice Concerning Non-Operating Income
2018.01.22
Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
2018.01.18
Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis
2018.01.15
Initiation of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2017.12.08
Analyst Report[Full report]: Shared Research updates the report
2017.11.30
Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company
2017.11.13
Initiation of an Arbitration against The Medicines Company
2017.11.10
Analyst Report[Update report]: Shared Research updates the report
2017.11.10
Notice Concerning Non-operating Income
2017.11.10
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
2017.11.02
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
2017.10.23
Analyst Report: Edison updates the report
2017.10.16
Analyst Report[Full report]: Shared Research updates the report
2017.10.10
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.09.21
Analyst Report[Update report]: Shared Research updates the report
2017.09.21
Notice of Revision to the Earnings Forecast for FY2017
2017.09.21
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
2017.09.20
Analyst Report[Full report]: Shared Research updates the report
2017.08.31
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2017.08.30
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
2017.08.25
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.08.03
Analyst Report[Update report]: Shared Research updates the report
2017.08.03
Notice Concerning Non-operating Income